Renalytix Plc
RNLX · NASDAQ
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.23 | -0.07 | -0.17 |
| FCF Yield | -221.91% | -27.22% | -55.76% | -2.40% |
| EV / EBITDA | -0.61 | -2.58 | -1.04 | -28.97 |
| Quality | ||||
| ROIC | -4,347.72% | -138.52% | -102.98% | -34.16% |
| Gross Margin | 6.82% | 20.60% | 30.91% | 46.08% |
| Cash Conversion Ratio | 0.90 | 0.71 | 0.92 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.32% | 31.66% | – | – |
| Free Cash Flow Growth | 7.83% | 29.64% | -76.83% | -130.92% |
| Safety | ||||
| Net Debt / EBITDA | -0.14 | 0.30 | 0.54 | 1.83 |
| Interest Coverage | 0.00 | 0.00 | -28,686.00 | -10,870.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.77 | 2.28 |
| Cash Conversion Cycle | -446.28 | -313.38 | -111.11 | -641.02 |